Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025893 | 0.87 | CHRNA7 (0.83) | CHRNA7CYP2D6 | |
| SCHEMBL3015623 | 0.87 | CHRNA7 (1.00) | CHRNA7CYP2D6 | |
| SCHEMBL3025950 | 0.86 | CHRNA7 (0.81) | CHRNA7CYP2D6 | |
| SCHEMBL3020486 | 0.86 | CHRNA7 (0.98) | CHRNA7CYP2D6 | |
| SCHEMBL3036238 | 0.85 | CHRNA7 (0.84) | CHRNA7CYP2D6 | |
| SCHEMBL3032113 | 0.85 | CHRNA7 (0.74) | CHRNA7CYP2D6 | |
| SCHEMBL3032110 | 0.85 | CHRNA7 (0.74) | CHRNA7CYP2D6 | |
| SCHEMBL3932755 | 0.85 | CHRNA7 (0.74) | CHRNA7CYP2D6 | |
| SCHEMBL3033700 | 0.85 | CHRNA7 (0.74) | CHRNA7CYP2D6 | |
| SCHEMBL3032833 | 0.85 | CHRNA7 (1.00) | CHRNA7CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250043285-A1 | Mammalian ATG8 Proteins and ATG9A Direct Sealing of Autophagosomal Membranes | UNM RAINFOREST INNOVATIONS (US) | 2025-02-06 | — | — | US | claimed |
| US-11878018-B1 | Phosphorylation of Syntaxin 17 by TBK1 controls autophagy initiation | UNM RAINFOREST INNOVATIONS (US) | 2024-01-23 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20220184036-A1 | METHODS OF TREATING HIV-ASSOCIATED NEUROLOGICAL DISORDERS (HAND) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-16 | — | — | US | claimed |
| WO-2018152554-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | ATTENUA, INC. (US) | 2018-08-23 | — | — | WO | claimed |
| US-8609713-B2 | Pyrrole derivatives and their methods of use | ABBVIE INC. (US) | 2013-12-17 | — | — | US | claimed |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | claimed |
| US-7741364-B2 | Neuronal nicotinic acetylcholine receptor modulators; such as ethyl 1-[4-(aminosulfonyl)phenyl]-5-(4-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate | ABBOTT LABORATORIES (US) | 2010-06-22 | — | — | US | claimed |
| CN-101479241-A | Pyrrole derivatives and their methods of use | ABBOTT LAB (US) | 2009-07-08 | — | — | CN | claimed |
| EP-2041085-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-04-01 | — | — | EP | claimed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | claimed |
| WO-2008002974-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | claimed |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12594270-B2 | Schizophrenic disorder treatment using combination therapy | CAMBRIDGE COGNITION LIMITED (GB) | 2026-04-07 | — | — | US | disclosed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| CN-101479241-A | Pyrrole derivatives and their methods of use | ABBOTT LAB (US) | 2009-07-08 | — | — | CN | disclosed |
| EP-2041085-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| WO-2008002974-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | PYCR1, PPOX, DHPS | CHRNA7 4801/4885CYP2D6 253/4885 |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | CHRNA5, CHRNA2, CHRNA4 | CHRNA7 4/4885CYP2D6 3204/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | CHRNA7 83/4885CYP2D6 928/4885 |
| US-20250043285-A1 | Mammalian ATG8 Proteins and ATG9A Direct Sealing of Autophagosomal Membranes | ATG7, BECN1, ATG4A | CHRNA7 4630/4885CYP2D6 4872/4885 |
| US-11878018-B1 | Phosphorylation of Syntaxin 17 by TBK1 controls autophagy initiation | STXBP1, TBK1, STX18 | CHRNA7 1698/4885CYP2D6 4836/4885 |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | PYCR1, PPOX, DHPS | CHRNA7 4801/4885CYP2D6 253/4885 |
| US-12594270-B2 | Schizophrenic disorder treatment using combination therapy | CHRNA7, HTR7, CHRNA10 | CHRNA7 1/4885CYP2D6 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.